Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis

被引：0
作者：
Selvaraj Vimalraj
Krishnasamy Naidu Gopal Hariprabu
Mostafizur Rahaman
Periyasami Govindasami
Karthikeyan Perumal
Saravanan Sekaran
Dhanraj Ganapathy
机构：
[1] Indian Institute of Technology,Department of Applied Mechanics and Biomedical Engineering
[2] Madras,Centre for Biotechnology
[3] Anna University,Department of Chemistry, College of Science
[4] King Saud University,Department of Chemistry and Biochemistry
[5] The Ohio State University,Department of Prosthodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS)
[6] Saveetha University,undefined
来源：
3 Biotech | 2023年 / 13卷
关键词：
Tumor; VEGFR-3; VEGF-C; Lymphangiogenesis; Angiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The cancer-promoting ligand vascular endothelial growth factor-C (VEGF-C) activates VEGF receptor-3 (VEGFR-3). The VEGF-C/VEGFR-3 axis is expressed by a range of human tumor cells in addition to lymphatic endothelial cells. Activating the VEGF-C/VEGFR-3 signaling enhances metastasis by promoting lymphangiogenesis and angiogenesis inside and around tumors. Stimulation of VEGF-C/VEGFR-3 signaling promotes tumor metastasis in tumors, such as ovarian, renal, pancreatic, prostate, lung, skin, gastric, colorectal, cervical, leukemia, mesothelioma, Kaposi sarcoma, and endometrial carcinoma. We discuss and update the role of VEGF-C/VEGFR-3 signaling in tumor development and the research is still needed to completely comprehend this multifunctional receptor.
引用
收藏
相关论文
共 703 条
[1]  
Achen MG(1998)Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) Proc Natl Acad Sci USA 95 548-553
[2]  
Jeltsch M(2014)Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice Clin Genitourin Cancer 15 1344-1356
[3]  
Kukk E(2016)Macrophage-induced lymphangiogenesis and metastasis following paclitaxel chemotherapy is regulated by VEGFR3 Cell Rep 17 1248-1264
[4]  
Mäkinen T(2019)VEGF in signaling and disease: beyond discovery and development Cell 176 457-464
[5]  
Vitali A(2003)Clinical significance of vascular endothelial growth factor c and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma Cancer 97 489-500
[6]  
Wilks AF(2015)Vascular remodeling is governed by a VEGFR3-dependent fluid shear stress set point Elife 4 110-114
[7]  
Alitalo K(2007)Vascular endothelial growth factor can signal through platelet-derived growth factor receptors J Cell Biol 177 370-377
[8]  
Stacker SA(2012)Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signaling Nature 484 700-709
[9]  
Alishekevitz D(2013)Nuclear EGFR as a molecular target in cancer Radiother Oncol 108 92-400
[10]  
Gingis-Velitski S(2019)Platelet-derived growth factor-D Enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma J Hepatol 70 393-9011
12345678910